Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Provencio

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 30, 2021
Future care for long-term cancer survivors: towards a new modelM Provencio, N Romero, J Tabernero, et al.
ESMO Open|June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysisU Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer GroupJ Remon, E Nadal, M Dómine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study GroupE Zucca, A Conconi, T I Mughal, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trialR A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trialS Michels, B Massutí, I Vasyliv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
ESMO Open|April 3, 2025
LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional studyA V Ospina-Serrano, A Collazo-Lorduy, E Azkona-Uribelarrea, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 30, 2021
Future care for long-term cancer survivors: towards a new modelM Provencio, N Romero, J Tabernero, et al.
ESMO Open|June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysisU Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer GroupJ Remon, E Nadal, M Dómine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study GroupE Zucca, A Conconi, T I Mughal, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trialR A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trialS Michels, B Massutí, I Vasyliv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
ESMO Open|April 3, 2025
LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional studyA V Ospina-Serrano, A Collazo-Lorduy, E Azkona-Uribelarrea, et al.
Pageof 11